MarginsXMarginsX
Home › Markets › Health Care › SGMT

Sagimet Biosciences Inc. Series A (SGMT)

SGMT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.13
-0.88% on the day
Market cap
$723.0M
Small cap
Revenue · 2023
$2.0M
No prior year to compare
Net income · 2023
-$27.9M
-1393.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1400118/000155837025002747/0001558370-25-002747-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerSGMT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2023
SEC CIK0001400118
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2023

LineValue
Revenue$2.0M
Net income-$27.9M
Operating income-$30.7M
Net margin-1393.8%
Operating margin-1537.0%
Revenue growthNo prior-year revenue to compare
Cash$75.1M
Total assets$96.7M
P/E (computed)Net income was not positive
P/S (computed)361.5×

Warning signs

Cash runway
30.5 months
$111.0M cash at September 30, 2026
Share count, 1 year
No year-earlier count
+233.9% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$4.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$111.0M cash; operating cash flow -$10.9M a quarter.Report 2026-09-30
Shares outstanding71,367,877 (2026-11-05); 21,375,402 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-10-01
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months8-K 4.01 2025-08-22
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$19.1M-$12.1M$111.0MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$14.0M-$11.1M$165.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$10.7M-$8.6M$36.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$9.6M-$11.8M$35.0MNo debt tagsNeeds four quarters10-K 2026-03-11
Q3 2025
2025-09-30
Not filed-$12.9M-$10.2M$32.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$10.4M-$9.1M$42.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$18.2M-$14.5M$64.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$16.2M-$11.0M$75.8MNo debt tagsNeeds four quarters10-K 2026-03-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-01
Latest annual report10-K2026-03-11
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-04-21

Source: SEC EDGAR submissions feed, 267 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.8%
1 month+28.1%
3 months+10.1%
Year to date+72.6%
1 year+32.0%
From 52-week high-10.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OBXObsidian Therapeutics Inc.$12.36-1.59%$763.5M
ANNXAnnexon Inc.$3.57-8.93%$681.0M
APMDApnimed Inc.$16.28-3.78%$677.7M
ARDXArdelyx Inc.$3.07-0.65%$771.7M
LXRXLexicon Pharmaceuticals Inc.$1.75-2.23%$779.2M
ORICOric Pharmaceuticals Inc.$7.52-4.33%$779.5M
JANXJanux Therapeutics Inc.$10.92-3.96%$668.1M
ALMSAlumis Inc.$5.14-8.21%$667.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier